Home Healthcare Biotechnology mRNA Vaccines and Therapeutics Market

mRNA Vaccines and Therapeutics Market Size, Share & Trends Analysis Report By Applications (COVID-19 mRNA vaccines, Non-COVID-19 mRNA vaccines), By mRNA type (COVID-19, Non-COVID-19) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 08, 2026 | Author: Dhanashri B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Table Of Content

  1. Executive Summary
  2. Research Scope & Segmentation
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
  3. Market Opportunity Assessment
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
  4. Market Trends
    1. Drivers
    2. Market Warning Factors
    3. Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
  5. Market Assessment
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
  6. mRNA Vaccines and Therapeutics Market Size Analysis
    1. Introduction
    2. mRNA Vaccines and Therapeutics Market Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
      1. COVID-19 mRNA vaccines
        1. Commercialized Vaccines
        2. Pipeline Vaccines
      2. Non-COVID-19 mRNA vaccines
        1. Oncology
        2. Infectious Diseases
        3. Other Diseases
    3. mRNA Vaccines and Therapeutics Market Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
      1. COVID-19
        1. Nucleoside-Modified mRNA (modRNA)
        2. Unmodified mRNA
        3. Self-Amplifying mRNA
      2. Non-COVID-19
        1. Nucleoside-Modified mRNA (modRNA)
        2. Unmodified mRNA
        3. Self-Amplifying mRNA)
  7. North America mRNA Vaccines and Therapeutics Market Size Analysis
    1. Introduction
    2. mRNA Vaccines and Therapeutics Market Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
      1. COVID-19 mRNA vaccines
        1. Commercialized Vaccines
        2. Pipeline Vaccines
      2. Non-COVID-19 mRNA vaccines
        1. Oncology
        2. Infectious Diseases
        3. Other Diseases
    3. mRNA Vaccines and Therapeutics Market Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
      1. COVID-19
        1. Nucleoside-Modified mRNA (modRNA)
        2. Unmodified mRNA
        3. Self-Amplifying mRNA
      2. Non-COVID-19
        1. Nucleoside-Modified mRNA (modRNA)
        2. Unmodified mRNA
        3. Self-Amplifying mRNA)
    4. U.S.
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    5. Canada
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
  8. Europe mRNA Vaccines and Therapeutics Market Size Analysis
    1. Introduction
    2. mRNA Vaccines and Therapeutics Market Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
      1. COVID-19 mRNA vaccines
        1. Commercialized Vaccines
        2. Pipeline Vaccines
      2. Non-COVID-19 mRNA vaccines
        1. Oncology
        2. Infectious Diseases
        3. Other Diseases
    3. mRNA Vaccines and Therapeutics Market Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
      1. COVID-19
        1. Nucleoside-Modified mRNA (modRNA)
        2. Unmodified mRNA
        3. Self-Amplifying mRNA
      2. Non-COVID-19
        1. Nucleoside-Modified mRNA (modRNA)
        2. Unmodified mRNA
        3. Self-Amplifying mRNA)
    4. U.K.
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    5. Germany
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    6. France
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    7. Spain
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    8. Italy
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    9. Russia
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    10. Nordic
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    11. Benelux
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    12. Rest of Europe
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
  9. APAC mRNA Vaccines and Therapeutics Market Size Analysis
    1. Introduction
    2. mRNA Vaccines and Therapeutics Market Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
      1. COVID-19 mRNA vaccines
        1. Commercialized Vaccines
        2. Pipeline Vaccines
      2. Non-COVID-19 mRNA vaccines
        1. Oncology
        2. Infectious Diseases
        3. Other Diseases
    3. mRNA Vaccines and Therapeutics Market Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
      1. COVID-19
        1. Nucleoside-Modified mRNA (modRNA)
        2. Unmodified mRNA
        3. Self-Amplifying mRNA
      2. Non-COVID-19
        1. Nucleoside-Modified mRNA (modRNA)
        2. Unmodified mRNA
        3. Self-Amplifying mRNA)
    4. China
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    5. Korea
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    6. Japan
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    7. India
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    8. Australia
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    9. Taiwan
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    10. South East Asia
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    11. Rest of Asia-Pacific
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
  10. Middle East and Africa mRNA Vaccines and Therapeutics Market Size Analysis
    1. Introduction
    2. mRNA Vaccines and Therapeutics Market Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
      1. COVID-19 mRNA vaccines
        1. Commercialized Vaccines
        2. Pipeline Vaccines
      2. Non-COVID-19 mRNA vaccines
        1. Oncology
        2. Infectious Diseases
        3. Other Diseases
    3. mRNA Vaccines and Therapeutics Market Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
      1. COVID-19
        1. Nucleoside-Modified mRNA (modRNA)
        2. Unmodified mRNA
        3. Self-Amplifying mRNA
      2. Non-COVID-19
        1. Nucleoside-Modified mRNA (modRNA)
        2. Unmodified mRNA
        3. Self-Amplifying mRNA)
    4. UAE
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    5. Turkey
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    6. Saudi Arabia
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    7. South Africa
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    8. Egypt
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    9. Nigeria
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    10. Rest of MEA
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
  11. LATAM mRNA Vaccines and Therapeutics Market Size Analysis
    1. Introduction
    2. mRNA Vaccines and Therapeutics Market Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
      1. COVID-19 mRNA vaccines
        1. Commercialized Vaccines
        2. Pipeline Vaccines
      2. Non-COVID-19 mRNA vaccines
        1. Oncology
        2. Infectious Diseases
        3. Other Diseases
    3. mRNA Vaccines and Therapeutics Market Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
      1. COVID-19
        1. Nucleoside-Modified mRNA (modRNA)
        2. Unmodified mRNA
        3. Self-Amplifying mRNA
      2. Non-COVID-19
        1. Nucleoside-Modified mRNA (modRNA)
        2. Unmodified mRNA
        3. Self-Amplifying mRNA)
    4. Brazil
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    5. Mexico
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    6. Argentina
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    7. Chile
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    8. Colombia
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
    9. Rest of LATAM
      1. Introduction
      2. Market Size & Forecast By Applications 2022-2034 (USD MILLION/ Units)
        1. COVID-19 mRNA vaccines
          1. Commercialized Vaccines
          2. Pipeline Vaccines
        2. Non-COVID-19 mRNA vaccines
          1. Oncology
          2. Infectious Diseases
          3. Other Diseases
      3. Market Size & Forecast By mRNA type 2022-2034 (USD MILLION/ Units)
        1. COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA
        2. Non-COVID-19
          1. Nucleoside-Modified mRNA (modRNA)
          2. Unmodified mRNA
          3. Self-Amplifying mRNA)
  12. Competitive Landscape
    1. mRNA Vaccines and Therapeutics Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    3. Tier Structure Analysis
    4. Recent Developments
  13. Market Players Assessment
    1. Arcturus Therapeutics Holdings Inc
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. BioNTech SE
    3. Daiichi Sankyo Company
    4. CureVac N.V
    5. Limited
    6. ethris GmbH
    7. GlaxoSmithKline plc
    8. Gennova Biopharmaceuticals Ltd
    9. Genova Biopharmaceuticals Ltd
    10. Moderna Inc
    11. Panthera Therapeutics GmbH
    12. Providence Therapeutics
    13. Silence Therapeutics
  14. Research Methodology
    1. Research Data
      1. Secondary Data
        1. Major Secondary Sources
        2. Key Data from Secondary Sources
      2. Primary Data
        1. Key Data from Primary Sources
        2. Breakdown of Primaries
      3. Secondary And Primary Research
        1. Key Industry Insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
  15. Appendix
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  16. Disclaimer
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.